Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Terns Pharmaceuticals (TERN) Profit After Tax (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Profit After Tax readings, the most recent being -$23.6 million for Q4 2025.

  • Quarterly Profit After Tax fell 8.13% to -$23.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$96.2 million through Dec 2025, down 8.28% year-over-year, with the annual reading at -$96.2 million for FY2025, 8.28% down from the prior year.
  • Profit After Tax hit -$23.6 million in Q4 2025 for Terns Pharmaceuticals, up from -$24.6 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$10.7 million in Q2 2021 and bottomed at -$29.8 million in Q3 2023.
  • Average Profit After Tax over 5 years is -$19.3 million, with a median of -$21.3 million recorded in 2023.
  • The largest annual shift saw Profit After Tax tumbled 76.97% in 2023 before it rose 26.28% in 2024.
  • Terns Pharmaceuticals' Profit After Tax stood at -$14.2 million in 2021, then dropped by 11.05% to -$15.8 million in 2022, then crashed by 32.85% to -$21.0 million in 2023, then decreased by 3.71% to -$21.8 million in 2024, then dropped by 8.13% to -$23.6 million in 2025.
  • Per Business Quant, the three most recent readings for TERN's Profit After Tax are -$23.6 million (Q4 2025), -$24.6 million (Q3 2025), and -$24.1 million (Q2 2025).